ARTICLE | Product Development
How Gilead deal positions Galapagos to become Europe’s next big biotech
Gilead deal sets Galapagos up as a European leader and provides template others can follow
July 27, 2019 12:30 AM UTC
Updated on Feb 14, 2020 at 6:54 PM UTC
Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow.
The July 14 deal not only provides Galapagos N.V. with over $5 billion for R&D expansion or strategic acquisitions, it’s also structured to ensure that neither partner Gilead Sciences Inc., nor any other company, can acquire the Belgian biotech over the next 10 years...